Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 116.14 billion. The enterprise value is 130.67 billion.

Market Cap	116.14B
Enterprise Value	130.67B

Important Dates

The last earnings date was Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	Jun 13, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+0.28%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.04 and the forward PE ratio is 12.67.

PE Ratio	21.04
Forward PE	12.67
PS Ratio	4.37
PB Ratio	6.58
P/TBV Ratio	n/a
P/FCF Ratio	12.75
P/OCF Ratio	12.11
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 14.35.

EV / Earnings	23.68
EV / Sales	5.06
EV / EBITDA	10.46
EV / EBIT	13.27
EV / FCF	14.35

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.31.

Current Ratio	1.37
Quick Ratio	1.06
Debt / Equity	1.31
Debt / EBITDA	1.80
Debt / FCF	2.53
Interest Coverage	11.14

Financial Efficiency

Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.79%.

Return on Equity (ROE)	32.66%
Return on Assets (ROA)	12.14%
Return on Invested Capital (ROIC)	15.79%
Return on Capital Employed (ROCE)	24.84%
Revenue Per Employee	1.51M
Profits Per Employee	313,569
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.45

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +48.74% in the last 52 weeks. The beta is 0.28, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.28
52-Week Price Change	+48.74%
50-Day Moving Average	97.88
200-Day Moving Average	86.67
Relative Strength Index (RSI)	46.03
Average Volume (20 Days)	1,728

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.40

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 26.59 billion and earned 5.52 billion in profits. Earnings per share was 4.38.

Revenue	26.59B
Gross Profit	20.81B
Operating Income	10.13B
Pretax Income	6.31B
Net Income	5.52B
EBITDA	12.70B
EBIT	10.13B
Earnings Per Share (EPS)	4.38

Full Income Statement

Balance Sheet

The company has 8.06 billion in cash and 23.09 billion in debt, giving a net cash position of -15.03 billion.

Cash & Cash Equivalents	8.06B
Total Debt	23.09B
Net Cash	-15.03B
Net Cash Per Share	n/a
Equity (Book Value)	17.65B
Book Value Per Share	14.24
Working Capital	4.22B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.59 billion and capital expenditures -482.95 million, giving a free cash flow of 9.11 billion.

Operating Cash Flow	9.59B
Capital Expenditures	-482.95M
Free Cash Flow	9.11B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.29%, with operating and profit margins of 38.11% and 20.76%.

Gross Margin	78.29%
Operating Margin	38.11%
Pretax Margin	23.75%
Profit Margin	20.76%
EBITDA Margin	47.76%
EBIT Margin	38.11%
FCF Margin	34.26%

Dividends & Yields

This stock pays an annual dividend of 2.87, which amounts to a dividend yield of 3.08%.

Dividend Per Share	2.87
Dividend Yield	3.08%
Dividend Growth (YoY)	2.99%
Years of Dividend Growth	10
Payout Ratio	66.02%
Buyback Yield	-0.28%
Shareholder Yield	2.81%
Earnings Yield	4.75%
FCF Yield	7.84%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.19.

Altman Z-Score	3.19
Piotroski F-Score	n/a